Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Antiviral Drug Arbidol Inhibits Infection by SARS-CoV-2 and Variants through Direct Binding to the Spike Protein.

ACS chemical biology - 17 Dec 2021

Shuster Anton, Pechalrieu Dany, Jackson Cody B, Abegg Daniel, Choe Hyeryun, Adibekian Alexander

Abstract excerpt

Arbidol (ARB) is a broad-spectrum antiviral drug approved in Russia and China for the treatment of influenza. ARB was tested in patients as a drug candidate for the treatment at the early onset of COVID-19 caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite promising clinical results and multiple ongoing trials, preclinical data are lacking and the molecular mechanism of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to A549 Cells
Share to Indoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lysosomes

Share to Protein Domains

Share to Proteolysis

Share to Spike Glycoprotein, Coronavirus

Share to Vero Cells

Share to Virus Internalization

Source

Identifiers

PMID: 34792325
DOI: 10.1021/acschembio.1c00756

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Antiviral Drug Arbidol Inhibits Infection by SARS-CoV-2 and Variants through Direct Binding to the Spike Protein.PMID 34792325Read ↗

Research Progress on Spike-Dependent SARS-CoV-2 Fusion Inhibitors and Small Molecules Targeting the S2 Subunit of SpikeSemantic proximity Read ↗

Targeting an evolutionarily conserved “E-L-L” motif in the spike protein to develop a small molecule fusion inhibitor against SARS-CoV-2Semantic proximity Read ↗

How Does Arbidol Inhibit the Novel Coronavirus SARS-CoV-2? Atomistic Insights from Molecular Dynamics SimulationsSemantic proximity Read ↗

Targeting an evolutionarily conserved “E-L-L” motif in spike protein to identify a small molecule fusion inhibitor against SARS-CoV-2Semantic proximity Read ↗

Annual SZ® A Novel Formulation For COVID-19 Therapy Clinical Trial StudiesSemantic proximity Read ↗

Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2Semantic proximity Read ↗

High throughput screening identifies broad-spectrum Coronavirus entry inhibitorsSemantic proximity Read ↗

SARS-CoV-2 spike protein and RNA dependent RNA polymerase as targets for drug and vaccine development: A reviewSemantic proximity Read ↗

Screening of Botanical Drugs against SARS-CoV-2 EntrySemantic proximity Read ↗

Human embryonic stem cell-derived cardiomyocyte platform screens inhibitors of SARS-CoV-2 infectionSemantic proximity Read ↗

Efficacy and Safety Evaluation of Arbidol in Patients with COVID-19Semantic proximity Read ↗

Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitorSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.